..........

. . . . . . . . . .

Executive Summary of Hypermed, Inc. A biomedical company with an U.S. patent (patent number 6669661), additional patent-pending devices & technologies, generating annual revenue of one million dollars, and planning to

(1) Treat cancers & AIDS with whole-body profound hyperthermia,

(2) Prevent Brain and Spinal Cord damage with hypothermia,

(3) Reduce hospital-acquired infections and public space pandemics,

(4) Stop opiate addiction without withdrawal in 8 hours & no relapse.

WEBSITES: www.Hypermed.us & www.rapiddetoxlasvegas.com

Founder and CEO:  Thomas C. Yee, MD MBA,Board Certified by American Board of Anesthesiology & American Board of Pain Medicine, 21 years experience in cardiac anesthesia,Former Clinical Assistant Professor and chief of cardiac anesthesia, University of Nevada School of Medicine. TEL (800) 276-7021 E-mail: drthomasyee@gmail.com

Product and Services: 

(1) Hyperthermia to cure cancer and AIDS. See website www.hypermed.us   

(2) Hypothermia Cool-Head Device for brain protection in cardiac arrest, stroke, trauma

(3) Advanced Technology Ultra-Violet Germicidal Device for Sanitizing Hospitals

(4) Rapid Detox Technology to help people addicted to opiates quit without feeling withdrawal in 8 hours and stay off relapse indefinitely with FDA-approved medications. See website www.rapiddetoxlasvegas.com. Annual revenue $1,000,000 currently.

www.Hypermed.uswww.rapiddetoxlasvegas.com

DrThomasYee@gmail.com TEL (800) 276-7021

FilmWatch Division Marketing Plan 2

.........Business Model: 

(1) Hyperthermia cancer and AIDS treatment clinics will be set up as anchor clinics in key locations operated directly by Hypermed, and franchise out to satellite locations to achieve rapid market saturation in Asia, Europe, the Americas. The key clinics will be technology development and pioneering centers. Franchises will be operated by local physicians trained by Hypermed.

(2) Build and sell Hypothermia devices such as our patent-pending "Cool-Head" device will be sold directly to emergency rooms, ambulance companies, trauma centers, hospitals in the Americas, Europe and Asia to protect brains in patients who have suffered cardiac arrest, stroke, head trauma.

(3) Building and selling patent-pending Advanced Technology UVG Device to hospitals and public institutions to reduce hospital-acquired infections and endemics.

(4) Currently providing advanced rapid detox service to help people quit opiate addiction painlessly without withdrawal in 8 hours, now treating 96 patients per year, charging $13,000 to $15,000 per patient, generating annual revenue of one million USD, planning to expand capacity to treat 2,000 patients per year.

Revenue Model:

(1) Hyperthermia cancer and AIDS treatment clinics will charge $50,000 for each cancer and AIDS patient. In franchise clinics, Hypermed charges 50% franchise fee. Estimated market of 20,000 patients annually, Potential annual revenue of $500,000,000.

(2) Sale of "Cool-Head" devices at $2,500, 10,000 units per year; disposable unit at $800, 100,000 units per year. Potential annual revenue of $100,000,000.

(3) Ultra-Violet Germicidal Device to be sold at $50,000 per unit with annual sale of 5,000 units. Potential annual revenue of $250,000,000.

(4) Rapid detox already in operation at one location and generating one million USD annually now. Potential annual revenue $20,000,000 after expansion to 10 locations.

Picture: Prototype of Hypermed UVG Ultraviolet Device for portable, large-area sanitizing for prevention of infections and pandemics.

Competition: There is no cure for cancer, especially after the cancer has metastasized. For AIDS, the triple-drug cocktail costs $30,000 per year, and does not cure. We will offer curative treatment, either as a one-time treatment or as one-time plus periodic booster treatment. There is no other rapid detox medical technology comparable to Hypermed’s. Further, there is no portable high-output ultra violet large area-sanitizing device such as our UVG device.

Competitive Advantage: Hypermed owns the US patent (#6669661) and other undisclosed proprietary pharmacological and engineering know-hows in the field of brain and tissue protection during extreme physiological conditions such as hyperthermia and hypothermia. Currently, there is no effective cure for either cancer or AIDS. In our Hypermed Rapid Detox technology, there is no one else in the world doing what we do; stopping opiate addiction painlessly, without withdrawal, in just 8 hours, and preventing relapse indefinitely. In our UVG system, we have the only portable, high-output, large-area, sanitizing device.

Market Potential: A curative treatment for cancer and AIDS has a potential market of over $30 Billion per year, just in the US. World-wide the market is $60 Billion per year. Cool-Head device line technology targets the more than 1 million cases of cardiac arrests/stroke/head traumas per year in the US, translating to market potential of $700,000,000 per year. AT UVG Device annual revenue will be about $200,000,000. Through Rapid Detox Clinics annual revenue will be about $20,000,000.

Source & Date of Market Information: 500,000 Americans die from cancer every year. There are nearly 12 million Americans with cancer. (source: USA Today 3-13-07 and Journal of Oncology March 2007)  If only 5% of the 12 Million has the cash to pay for the curative treatment every year; that is $50,000 times 600,000, equaling $30,000,000,000 (30 Billion Dollars) per year. The population of affluent countries in Europe, Asia, Canada, South America totals 600,000,000 (twice the population of US) (source: the CIA World Fact Book 2007), with similar cancer incidence. Even if only 2.5% of these patients pay cash for Hypermed's treatment; that translates into another $30,000,000,000 per year.

AIDS patients in the affluent countries (including US) total at least 3 million. If 5% per year pays for the treatment for a cure, that translates to $7,500,000,000 per year.

In the Ultra Violet Germicidal Light device, selling at $50,000 per unit, selling to a market consisting of 5,000 hospitals in the U.S., 10,000 rehab centers and nursing homes, and 25,000 schools, train stations, bus stations, airports, and other public spaces in need of such large-area rapid sanitizing to reduce the chance of the spread of infection and pandemics. If 10% of such facility buys one unit per year, annual market is potentially $200,000,000.

In the U.S., forty thousand people die each year from opiate drug overdose due to addiction. (source: CDC report 2009) If 10% of such desperate addicts can pay $15,000 to have rapid detox procedure, that equals to potential annual market of $60,000,000.

Patent: US patent #6669661, Device and Technique in protection of central nervous system during hyperthermia an d hypothermia. This is the technology, including devices, systems, techniques, use of chemicals, pharmacological agents to achieve protection and preservation of the human central nervous system during extreme physiological conditions such as hyperthermia and hypothermia. By protecting the brain, this renders safe hyperthermia treatment for cancer and AIDS possible. Additional Intellectual Property: There are additional patent-pending technology on the Cool-Head device, the Ultra-Violet Light Germicidal Device, and the Rapid Detox Technology and Procedure.

FilmWatch Division Marketing Plan 2

.........

Funding Requirement

Seeking between 10 Million to 20 Million USD to fund expansion of operation, Hypermed Inc. is already generating annual revenue of one million USD. The new investment will represent between 10 to 20 percent of equity shares of the company. The fund will be used

(1) to expand the rapid detox operation to increase marketing and public relation in order to increase the current 1 million USD revenue to 10 million USD within 5 years.

(2) to manufacture and market devices and treatment systems to be used in curing cancer, AID, in protecting brains, and prevention of infections and pandemics. Raising annual revenue to from zero currently to 30 million USD in five years.

Conclusion

Hypermed, Inc. seeks investment of between $10,000,000 $20,000,000 in equity funding to support: (1) the animal and human studies for hyperthermia cure for cancer using the patented technology. (2) manufacturing, FDA approval application and initial marketing of the applied hypothermia device for brain protection, proto-type named Cool-Head device. (3) Marketing and production of Advanced Technology UVG Device. (4) Expansion of Rapid Detox Clinics and technology

Five Key Advantages:

(1) Hypermed already owns a US patent on its core technology [US patent #6669661].

(2) All animal studies and human studies are short-term, well-defined, and finite.

(3) Rapid Detox Medical Clinic is already generating revenue of $1,000,000 annually out of one location in Las Vegas, currently operational. Website is near the top of Google natural search result when searching for keywords “rapid detox”

(4) Short time horizon to enhanced positive cash flow for Rapid Detox Clinics, UVG device, and the Cool-Head device is short (24 months)

(5) Multiple technology/product lines; hyperthermia to cure cancer and AIDS and hypothermia device such as Cool-Head and Advanced Technology UVG Device ready for manufacturing and marketing, and Rapid Detox Clinics and technology.

 Please review our websites www.hypermed.us and www.rapiddetoxlasvegas.com for detailed information, supporting documentation, and testimonials.

www.rapiddetoxlasvegas.com is linked two other websites we own: www.rapid-detox-clinic.org and www.rapid-detox-center.org. When searching for key words “rapid detox” on any of the major search engines such as Google, Yahoo, and Bing our websites consistently appear among the top three results in the natural or organic search result listings. This dominance of web search engine result listing gives us powerful presence and helps us generate one million dollars in annual revenue for the past 3 years.

Business Plan of Hypermed, Inc.A biomedical technology company based in La Jolla, California and Las Vegas, Nevada, with US patent (patent number 6669661), with current annual revenue of 1 million USD, developing four lines of products and services stemming from patented and patent-pending technology and devices to (1) treat cancer and infections, (2) protect traumatized or ischemic human brains using advanced cooling system, (3) reduce hospital-acquired infection and epidemics with advanced ultra-violet germicidal device, (4) Controlling and protecting the human brain to stop opiate physical addiction in 8 hours, safely, without patients feeling withdrawal and without relapse.

Corporate Websites: www.Hypermed.us & www.rapid-detox-clinic.org

Contact: CEO Dr. Thomas Yee, MD MBA, (800) 276-7021, drthomasyee@gmail.com

Corporate Mission

Become the global technology and business leader in saving and extending meaningful lives.

Key Products & Technology

(1) Hyperthermia Technology to Treat Cancer and Infections. (U.S. Patent number 6669661)(2) Hypothermia “Cool-Head” Device to save traumatized brains (patent pending)(3) Advanced Ultra-Violet Germicidal Device to reduce hospital-acquired infections and

epidemic infections in public spaces (patent pending)(4) Advanced Opiate Addiction Stoppage System (OASIS protocol, patent pending)

Revenue Stage: Currently generating $1 million USD per year, for the last 3 years.

Science Team Dr. Matthew Cooper, MD FACSformer Clinical Assistant Professor, Department of SurgeryUniversity of Nevada School of Medicine

Dr. Kevin Murray, MD FACS, former Chief of Cardiac Surgery, University of Nevada School of Medicine

Dr. James Yee, Ph.D.Electrical Engineering Ph.D. University of California, Berkeley

Management TeamPresident, CEO Thomas C. Yee, MD MBA

Vice President Dr. Jason Yee, Ph.D.Electrical Engineering Ph.D., Princeton University

Patented and Patent-Pending Technology and Devices

FilmWatch Division Marketing Plan 2

.........“Method and Device for Central Nervous System Protection During Whole Body Hyperthermia or Hypothermia” (US patent number 6669661)Patent-pending Cool-Head Device. Saves traumatized brains and spinal cords with advanced cooling and cerebral monitoring and control technology.

Patent-pending Advanced UVG Device. Reduces hospital-acquired infections and spread of epidemics in public space.

Patent-pending Rapid Detox Technology and Protocol to stop opiate addiction in 8 hours safely without withdrawal or relapse. See www.rapid-detox-clinic.org

Market and Potential Revenue for Treating Cancers with HyperthermiaLow Estimate: Approximately 500,000 persons die annually in the US due to cancer. Twice that

number die of cancer annually in affluent societies outside US, resulting in a total of 1,500,000 people. Hyperthermia treatment warrants compensations at least similar to heart bypass surgeries or to bone marrow transplant procedures, costing between $40,000 and $100,000. It is reasonable to price the Hyperthermia treatment at $50,000. Assuming only 10% of persons dying of cancer in affluent societies (150,000) seek Hyperthermia treatment, annual revenue will be 7.5 billion dollars. ($7,500,000,000)

High Estimate: 12 million Americans have cancer. (source: USA Today 3-13-07 and Journal of Oncology March 2007)  If only 5% of the 12 Million seek Hyperthermia per year, that equals $30,000,000,000. The population of affluent countries in Europe, Asia, Canada, South America totals 600,000,000 (twice the population of US) (source: the CIA World Fact Book 2007), with similar cancer incidence. Even if only 2.5% of these patients seek hyperthermia generates another $30,000,000,000 .

Market and Potential Revenue for Treating Viral DiseasesIn the US alone, there are more than two million people with HIV infection. Including all the affluent

societies in the world, more than five million people have the same infection. Tens of millions of people are infected with Hepatitis B and C that are otherwise incurable. Every year, tens of thousands of people die in the US from the flu. Around the world, as the recent SARS epidemic reminded us, influenza has the potential of killing hundreds of thousands of people. Assuming only a fraction of people in the affluent societies in the world with otherwise incurable viral infection (300,000) seek the Hyperthermia and Anti-Viral Combination treatment, the above figures would produce an annual revenue of $18,000,000,000

Market and Revenue Potential Revenue for Cool-Head hypothermia DeviceIn the US over one million head trauma cases per year result in pro-longed loss of consciousness. Over

500,000 cases of post-cardiac arrest loss of consciousness entail probable brain injury due to lack of oxygen. Every unconscious patient presenting to the emergency room or trauma center optimally require brain cooling and monitoring to increase chance of recovery. Global market is at least twice the size of the US market. Priced at $2,000 per patient, assuming only 50% of the eligible 1.5 million unconscious patients uses Cool-Head Device, the annual revenue in the US alone is $1,500,000,000.

Market and Potential Revenue for Advanced Ultra-Violet Germicidal DeviceHospital-acquired infection costs the hospitals in the US an average of $90,000 per case. There are

over five thousand hospitals in the US. There are over 30,000 nursing homes, long-care homes and assisted-living facilities. Every year in the US there are about 150,000 cases of serious hospital-acquired infections. Epidemics such as H1N1 flu and other pandemics cost the society significantly in lives and productivity lost. Global market is at least twice that of US market. Priced at $3,000 per device monthly rental rate, with over 35,000 facilities in the US and additional 10,000 facilities outside the U.S. requiring Hypermed UVG Device, at 4 devices per facility, the annual rental revenue is $500,000,000.

Market and Revenue Projection for rapid opiate detox technology and protocolIn the US, 40,000 Americans die from opiate overdose per year. Currently Las Vegas Rapid Detox

Medical Clinic, owned by Hypermed, Inc, charges $15,000 per procedure and performs 100 cases per year.Assuming 20,000 cases performed per year, under license to Hypermed, at a licensing fee of $5,000

per case, the annual revenue is projected to be $100,000,000.

Financing Hypermed seeks initial equity financing of between $10 and $20 million USD to fund the development, manufacturing, and marketing of the patented method and devices. This would represent between 10 to 20 percent of total equity shares.

Funding Need, Use of Funds and Time Table in Stages (Total $10,600,000 over 48 months)

Stage 1 Duration Twelve MonthsCool-Head Device Manufacturing cost $300,000

Marketing cost $200,000UVG Device Manufacturing cost $300,000

Marketing cost $200,000Hyperthermia Animal Study $800,000Rapid Detox PR and Marketing $200,000

------------------------------------------------------------------------------------Stage total funding needed $2,000,000

Stage 2 Duration Twelve MonthsCool-Head Device DEA app. cost $300,000

Manufacturing $300,000Marketing $200,000

UVG Device UL app cost $100,000Manufacturing $300,000Marketing $300,000

Hyperthermia Animal Study $1,500,000 Rapid Detox PR and Marketing $300,000

------------------------------------------------------------------------------------Stage total funding needed $3,300,000

Stage 3 Duration Twelve MonthsCool-Head Device Manufacturing $650,000

Marketing $350,000UVG Device Manufacturing $650,000

Marketing $350,000Hyperthermia Human Study $1,000,000Rapid Detox PR and marketing $300,000

-----------------------------------------------------------------------------------------------------Stage total funding needed $3,300,000

Stage 4 Duration Twelve Months Cool-Head Device Manufacturing $2,000,000

Marketing $1,000,000Revenue from Sales to cover cost ($2,500,000)

_______________________________________Net funding needed $500,000

UVG Device Manufacturing $2,000,000Marketing $1,000,000

Revenue from Sales to cover cost ($2,500,000)_______________________________________

FilmWatch Division Marketing Plan 2

......... Net funding needed $500,000Hyperthermia Device Human Study $1,000,000

------------------------------------------------------------------------------------------------------Stage total funding needed $2,000,000

Stage 5 Starting 48 months after initial fundingRevenue

Cool-Head Device Annual Sales $10,000,000UVG Device Annual Sales $10,000,000Hyperthermia Annual Sales $10,000,000Rapid Detox Annual Sales $5,000,000----------------------------------------------------------------------------------------------

Projected Annual Revenue $35,000,000

Stage 6 Starting 72 months after initial fundingRevenue

Cool-Head Device Annual Sales $30,000,000UVG Device Annual Sales $20,000,000Hyperthermia Annual Sales $40,000,000Rapid Detox Annual Sales $10,000,000

---------------------------------------------------------------------------------Projected Annual Revenue $100,000,000

Conclusion and Vision: This is a new technology company currently generating annual revenue of 1 million USD and owns patented key technology in the arena of cancer treatment, infection control and treatment, and brain protection. With an investment of between 10 to 20 million USD, investors are in positions to own significant equity of company that has the potential of attaining 100 million dollar annual revenue in 6 years.